Alaunos Therapeutics VP Finance resigns; Ferdinand Groenewald appointed as replacement via consulting agreement

Alaunos Therapeutics, Inc.

Michael Wong resigned as VP Finance effective Feb 23, 2024.
Ferdinand Groenewald appointed as VP Finance effective Feb 22, 2024 via consulting agreement.
Consulting agreement pays $15,000 per month; indefinite term with 30-day termination notice.
Groenewald previously served as CFO and CAO of Muscle Maker, Inc.; is a CPA.
Agreement includes customary indemnification and business expense reimbursement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Michael Wong

Vice President, Finance

TCRT · Alaunos Therapeutics, Inc.

Effective: 2024-02-23
Successor: Ferdinand Groenewald
Filed: February 22, 2024, 6:59 PM ET

On February 15, 2024, Michael Wong gave notice of his resignation as Vice President, Finance, of Alaunos Therapeutics, Inc. (the "Company"), effective February 23, 2024.

Appointed

Ferdinand Groenewald

Vice President, Finance

TCRT · Alaunos Therapeutics, Inc.

Effective: 2024-02-22
Filed: February 22, 2024, 6:59 PM ET

On February 22, 2024, the Company and Ferdinand Groenewald entered into a consulting agreement (the “Consulting Agreement”), effective February 22, 2024, pursuant to which Mr. Groenewald will lead accounting and financial reporting activities of the Company. Mr. Groenewald will serve as the Company’s Vice President, Finance.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Wong resigned as Vice President, Finance at Alaunos Therapeutics, Inc..

Action: resigned
Role: Vice President, Finance

Exact text from the filing

On February 15, 2024, Michael Wong gave notice of his resignation as Vice President, Finance, of Alaunos Therapeutics, Inc. (the "Company"), effective February 23, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ferdinand Groenewald was appointed as Vice President, Finance at Alaunos Therapeutics, Inc..

Action: appointed
Role: Vice President, Finance

Exact text from the filing

On February 22, 2024, the Company and Ferdinand Groenewald entered into a consulting agreement (the “Consulting Agreement”), effective February 22, 2024, pursuant to which Mr. Groenewald will lead accounting and financial reporting activities of the Company. Mr. Groenewald will serve as the Company’s Vice President, Finance.

View on SEC.gov

Alaunos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-042903

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.